BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16543921)

  • 1. Pharmacokinetics of oncolytic measles virotherapy: eventual equilibrium between virus and tumor in an ovarian cancer xenograft model.
    Peng KW; Hadac EM; Anderson BD; Myers R; Harvey M; Greiner SM; Soeffker D; Federspiel MJ; Russell SJ
    Cancer Gene Ther; 2006 Aug; 13(8):732-8. PubMed ID: 16543921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter.
    Hasegawa K; Pham L; O'Connor MK; Federspiel MJ; Russell SJ; Peng KW
    Clin Cancer Res; 2006 Mar; 12(6):1868-75. PubMed ID: 16551872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
    Liu C; Sarkaria JN; Petell CA; Paraskevakou G; Zollman PJ; Schroeder M; Carlson B; Decker PA; Wu W; James CD; Russell SJ; Galanis E
    Clin Cancer Res; 2007 Dec; 13(23):7155-65. PubMed ID: 18056196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
    Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
    Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal therapy of ovarian cancer using an engineered measles virus.
    Peng KW; TenEyck CJ; Galanis E; Kalli KR; Hartmann LC; Russell SJ
    Cancer Res; 2002 Aug; 62(16):4656-62. PubMed ID: 12183422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma.
    Blechacz B; Splinter PL; Greiner S; Myers R; Peng KW; Federspiel MJ; Russell SJ; LaRusso NF
    Hepatology; 2006 Dec; 44(6):1465-77. PubMed ID: 17133484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer.
    Myers R; Greiner S; Harvey M; Soeffker D; Frenzke M; Abraham K; Shaw A; Rozenblatt S; Federspiel MJ; Russell SJ; Peng KW
    Cancer Gene Ther; 2005 Jul; 12(7):593-9. PubMed ID: 15746945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.
    Hasegawa K; Nakamura T; Harvey M; Ikeda Y; Oberg A; Figini M; Canevari S; Hartmann LC; Peng KW
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6170-8. PubMed ID: 17062694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response.
    Gauvrit A; Brandler S; Sapede-Peroz C; Boisgerault N; Tangy F; Gregoire M
    Cancer Res; 2008 Jun; 68(12):4882-92. PubMed ID: 18559536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.
    Wei J; Wahl J; Nakamura T; Stiller D; Mertens T; Debatin KM; Beltinger C
    Gene Ther; 2007 Nov; 14(22):1573-86. PubMed ID: 17898797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered measles virus as a novel oncolytic therapy against prostate cancer.
    Msaouel P; Iankov ID; Allen C; Morris JC; von Messling V; Cattaneo R; Koutsilieris M; Russell SJ; Galanis E
    Prostate; 2009 Jan; 69(1):82-91. PubMed ID: 18973133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer.
    Galanis E; Hartmann LC; Cliby WA; Long HJ; Peethambaram PP; Barrette BA; Kaur JS; Haluska PJ; Aderca I; Zollman PJ; Sloan JA; Keeney G; Atherton PJ; Podratz KC; Dowdy SC; Stanhope CR; Wilson TO; Federspiel MJ; Peng KW; Russell SJ
    Cancer Res; 2010 Feb; 70(3):875-82. PubMed ID: 20103634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer.
    McDonald CJ; Erlichman C; Ingle JN; Rosales GA; Allen C; Greiner SM; Harvey ME; Zollman PJ; Russell SJ; Galanis E
    Breast Cancer Res Treat; 2006 Sep; 99(2):177-84. PubMed ID: 16642271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies.
    Ong HT; Hasegawa K; Dietz AB; Russell SJ; Peng KW
    Gene Ther; 2007 Feb; 14(4):324-33. PubMed ID: 17051248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heat shock protein inhibitors increase the efficacy of measles virotherapy.
    Liu C; Erlichman C; McDonald CJ; Ingle JN; Zollman P; Iankov I; Russell SJ; Galanis E
    Gene Ther; 2008 Jul; 15(14):1024-34. PubMed ID: 18356818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling of cancer virotherapy with recombinant measles viruses.
    Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D
    J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases.
    Springfeld C; von Messling V; Frenzke M; Ungerechts G; Buchholz CJ; Cattaneo R
    Cancer Res; 2006 Aug; 66(15):7694-700. PubMed ID: 16885371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.